We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Justice Department filed notice that it plans to intervene in four False Claims Act lawsuits accusing Indivior and Reckitt of improperly marketing the opioid anti-addiction drug Suboxone. Read More
Taking aim at illicit synthetic opioid distribution, the Department of Justice is launching a Florida operation to prosecute every case of illegal distribution. Read More
Some pharmacies “billed extremely high amounts” for at least one of five measures that OIG has developed as indicators of possible fraud, waste or abuse. Read More
The health department says the plan would cost less than what the state currently spends on hepatitis C drugs for the Medicaid and prison populations. Read More
The FDA warned Montreal, Quebec-based drugmaker Les Produits Chimiques over serious quality unit failures that caused its APIs to be adulterated. Read More
The Louisiana Department of Health is considering subscription-based payments for manufacturers of hepatitis C drugs as a way to control the state’s spending on drugs and to serve more Medicaid patients. Read More
The HHS Office of Inspector General flagged “questionable billing” and rapid growth in Medicare Part D spending for compounded topical drugs in a report released Thursday. Read More
Drug sponsors may not have to prove that a proposed medicine-assisted therapy helps addicts completely kick opioids but they will have to detail how well it helps cut dependence to win FDA approval, the agency said in a new draft guidance. Read More
AstraZeneca filed suit against generic manufacturer Accord Pharmaceuticals for alleged infringement upon four patents for AstraZeneca’s breast cancer drug Faslodex (fulvestrant). Read More